Urticaria: Clinical Trials

532 trials for Urticaria, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

316 completed, 52 recruiting, 45 terminated, 42 unknown. 141 Phase 3, 138 Phase 2, 71 Phase 1, 40 Phase 4, 32 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 3141Completed 96, Active not recruiting 12, Recruiting 9, Terminated 8, Unknown 6, Enrolling by invitation 5, Withdrawn 3, Not yet recruiting 2
Phase 2138Completed 74, Terminated 20, Recruiting 12, Unknown 9, Withdrawn 8, Not yet recruiting 7, Active not recruiting 6, Enrolling by invitation 2
Phase 171Completed 44, Terminated 8, Recruiting 7, Active not recruiting 4, Not yet recruiting 4, Unknown 2, Withdrawn 2
Phase 440Completed 25, Unknown 7, Recruiting 3, Terminated 3, Withdrawn 2
Not applicable32Completed 12, Unknown 6, Recruiting 5, Not yet recruiting 3, Terminated 3, Withdrawn 2, Suspended 1
Early Phase 14Completed 2, Active not recruiting 1, Terminated 1

Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt
No intervention - Hereditary Angioedema (HAE)
Not yet recruitingTakeda1002026-12-012026-06-18
The Proteome of Chronic Urticaria
Punch biopsy - Chronic Urticaria
Not yet recruitingZealand University Hospital802026-12-012026-11-16
Remibrutinib in Real-world Clinical Practice - a South Korea Sub-Study
Chronic Spontaneous Urticaria
Not yet recruitingNovartis Pharmaceuticals5782026-11-302026-11-05
Phase I Study to Evaluate Single and Multiple Oral Doses of HW281171 Tablets in Healthy Participants
HW281171 tablets, Placebo tablets - Chronic Urticaria
Phase 1Not yet recruitingHubei Bio-Pharmaceutical Industrial Technological Institute Inc.802026-11-182026-11-13
A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria
AK139, Placebo - Chronic Spontaneous Urticaria
Phase 2Not yet recruitingAkeso2012026-10-212026-10-15
A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria (CSU)
NN2802 - Healhty, Chronic Spontaneous Urticaria (CSU)
Phase 1 / Phase 2RecruitingNovelty Nobility, Inc.462026-10-152026-11-12
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
MG-K10 Injection, Matching Placebo - Chronic Urticaria, Idiopathic
Phase 2Not yet recruitingShanghai Mabgeek Biotech.Co.Ltd602026-09-232026-09-24
Apremilast Added to Antihistamines in Chronic Urticaria
Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria
Phase 2Enrolling by invitationRashid Latif Medical College862026-09-232026-09-30
A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
No intervention - Hereditary Angioedema (HAE)
RecruitingTakeda352026-09-212026-10-15
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria
Phase 3RecruitingNovartis Pharmaceuticals3822026-09-212026-11-09
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335 Lower Dose, THB335 Higher Dose, Placebo - Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Phase 2RecruitingCalixis Inc.812026-09-152026-11-02
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs
TLL-018 tablets, Placebo - Chronic Spontaneous Urticaria (CSU)
Phase 2Not yet recruitingHangzhou Highlightll Pharmaceutical Co., Ltd1402026-09-102026-08-24
A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology
Flexible ePROM-guided Scheduling System, electronic patient reported outcome measures (ePROMs) - Chronic Dermatological Conditions, Eczema
Not applicableNot yet recruitingNational University Hospital, Singapore2502026-09-012026-07-01
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
KVD900 600 mg - Hereditary Angioedema
Phase 4RecruitingKalVista Pharmaceuticals, Ltd.1002026-08-172026-09-17
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU)
Phase 1 / Phase 2Not yet recruitingHangzhou Highlightll Pharmaceutical Co., Ltd362026-08-152026-08-24
Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)
Chronic Spontaneous Urticaria
RecruitingNovartis Pharmaceuticals4702026-08-042026-08-07
A Trial of HRS-3095 in Healthy Volunteers
HRS-3095 - Chronic Spontaneous Urticaria
Early Phase 1Active not recruitingAtridia Pty Ltd.362026-07-272026-10-30
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
HRS-3095 Tablet, HRS-3095 Tablet Placebo - Chronic Spontaneous Urticaria
Phase 2Not yet recruitingChengdu Suncadia Medicine Co., Ltd.1902026-07-012026-05-29
Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).
Alpha-0261, Placebo - Chronic Spontaneous Urticaria (CSU), Healthy Volunteers
Phase 1Not yet recruitingAlphaMol Science Ltd. (Shanghai)482026-07-012026-07-06
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
BBT001, Placebo - Chronic Spontaneous Urticaria
Phase 1 / Phase 2RecruitingBambusa Therapeutics482026-06-292026-07-22

Showing 20 of 532. Sign in to see all of them.

Narrower conditions

Chronic Urticaria (195)  ·  Angioedemas, Hereditary (169)  ·  Angioedema (64)  ·  Cryopyrin-Associated Periodic Syndromes (35)  ·  Hypersensitivity (23)  ·  Pruritus (23)  ·  Asthma (17)  ·  Chronic Inducible Urticaria (17)  ·  Hereditary Angioedema Types I and II (17)  ·  Cold Urticaria (16)  ·  Rhinitis, Allergic (16)  ·  Dermatitis, Atopic (14)  ·  Skin Diseases (14)  ·  Immune System Diseases (10)

Broader conditions

Skin and Connective Tissue Diseases (532)  ·  Hypersensitivity, Immediate (526)  ·  Skin Diseases, Vascular (526)  ·  Immune System Diseases (522)  ·  Skin Diseases (518)  ·  Hypersensitivity (509)  ·  Pathological Conditions, Signs and Symptoms (271)  ·  Pathologic Processes (256)  ·  Disease Attributes (250)  ·  Chronic Disease (241)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (221)  ·  Cardiovascular Diseases (213)  ·  Vascular Diseases (213)  ·  Genetic Diseases, Inborn (212)

Interventions

Omalizumab (44)  ·  Complement C1 Inhibitor Protein (28)  ·  desloratadine (18)  ·  icatibant (15)  ·  levocetirizine (15)  ·  lanadelumab (13)  ·  remibrutinib (13)  ·  berotralstat (12)  ·  canakinumab (12)  ·  conestat alfa (11)  ·  Sodium Chloride (10)  ·  ligelizumab (10)  ·  bilastine (9)  ·  sebetralstat (9)  ·  SERPING1 protein, human (8)

Sponsors

Novartis Pharmaceuticals (49)  ·  Shire (40)  ·  Takeda (20)  ·  BioCryst Pharmaceuticals (17)  ·  CSL Behring (15)  ·  Charite University, Berlin, Germany (15)  ·  KalVista Pharmaceuticals, Ltd. (13)  ·  Organon and Co (11)  ·  Genentech, Inc. (10)  ·  Celldex Therapeutics (8)  ·  Pharming Technologies B.V. (8)  ·  Pharvaris Netherlands B.V. (8)  ·  University Hospital, Grenoble (8)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (7)  ·  Ionis Pharmaceuticals, Inc. (6)

Countries

United States (209)  ·  Germany (151)  ·  France (91)  ·  Canada (90)  ·  Spain (83)  ·  United Kingdom (80)  ·  Italy (68)  ·  Poland (67)  ·  Hungary (51)  ·  China (49)  ·  Japan (48)  ·  Netherlands (47)  ·  Australia (46)  ·  Bulgaria (42)  ·  Israel (42)

Top investigators

Marcus Maurer, MD (7)  ·  Anurag Relan, MD (4)  ·  Jill A Poole, MD (3)  ·  Lauge Farnaes, MD (3)  ·  M. M. Levi, Prof. Dr. (3)  ·  Marcus Maurer, Prof. (3)  ·  Peter Bauer, MD (3)

Results publications

PMID 36326435, PMID 36408587, PMID 20818886, PMID 23312695, PMID 23878046, PMID 24712435, PMID 23548529, PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 42159953, PMID 42268494, PMID 17021840, PMID 20818888, PMID 20819318, PMID 20920772, PMID 21130380, PMID 22765833, PMID 22856635, PMID 23484892, PMID 23548526, PMID 23987198, PMID 25104279, PMID 25198193, PMID 28284978, PMID 31161734, PMID 34773261, PMID 36153561, PMID 36440464, PMID 36774155, PMID 37028510, PMID 38008109, PMID 39193419, PMID 40043237, PMID 40171989, PMID 40380356, PMID 40469312, PMID 40769455, PMID 40886933, PMID 42297099, PMID 42318595, PMID 12384926, PMID 12874849, PMID 14982513, PMID 15201414, PMID 15208377, PMID 15334472

NIH funding

2019 (10), 2023 (7), 2018 (6), 2015 (5), 2014 (4), 2009 (3), 2017 (3), 2025 (3), 2004 (2), 2008 (2), 2016 (1), R01AI116658 (1), R01HL079184 (1), R01HL082925 (1), ZIAAR041138-08 (1)